The Outlier Trap: Why One Big Customer Is Not a Market

How a single marquee partner can convince you that you have validation when what
you have is a coincidence

Every founder of a disruptive technology company will, at some point, get the phone call. A name-brand company — a Merck, a Google, a J.P. Morgan, a Mayo Clinic — has decided to engage. They want to pilot the product. They are willing to invest. They are willing to co-publish. They are willing, in some cases, to put non-trivial money on the table. The temptation in that moment is enormous, and it is also dangerous. Because what feels like the launchpad of a rocket ship is, more often than not, an outlier wearing the costume of a market signal.

One innovator is not a market. One innovator is a coincidence with a logo.

Diagnostic Biochips, a neurotechnology company, lived through this exact scenario. The team had spent years building best-in-class implantable sensors for in vivo neuroscience research. As they considered their next act — moving into preclinical drug discovery via brain organoid measurement — Merck stepped forward. As a customer and partner. They invested in discovery, contributed biology expertise, and co-published the science. By any reasonable measure, this looked like the kind of validation founders dream of.

The natural conclusion was the obvious one: we have a Merck, so let's go get two or three more Mercks. This is the moment, in retrospect, when the company could very easily have ended its own story. Because had the team accepted that conclusion at face value, they would have built an entirely different — and entirely wrong — product.

What the conventional path would have looked like

If the Merck signal had been treated as market validation, the next move would have been to scale to a high-throughput screening instrument. Ninety-six wells minimum, perhaps more. Industrial-grade automation. The kind of capital equipment that big pharma discovery groups deploy at scale. The team would have raised a substantial round to fund that build, hired aggressively against it, and shipped a product that — based on what they later learned — almost no other pharma company in the world was ready to buy.

That is the Innovation Death Spiral in slow motion. A single outlier signal interpreted as a market signal, an enormous capital deployment against that signal, and twelve to eighteen months later a sales team with a beautiful product and no buyers. The graveyard of innovation is full of companies that built the right product for the wrong customer, then ran out of cash before they could course correct.

The intervention: skepticism as discipline

The Sell Now™ Sales Playbook is built on a foundational principle from the Cynefin framework: in a complex domain, you do not plan and execute, you probe and learn. The role of leadership is to keep the team in discovery mode, not to push them into execution mode prematurely. When a Merck-sized signal arrives, the disciplined response is not “let's get more,” it is “let's go find out whether this is a pattern or an exception.”

In DBC's case, that meant systematic customer discovery across the rest of pharma — dozens of conversations with discovery groups, assay development teams, and translational researchers. The hypothesis under test was simple: are there other Mercks out there, ready to engage at a similar level? The answer, after dozens of interviews, was unambiguous. Merck was a true outlier. No one else in pharma was at that level of readiness. Not even close.

That answer would have been devastating if the team had already raised a round and built the high-throughput screening instrument. Instead, because the discovery happened before the commitment, it was simply useful information. The Merck partnership was preserved. The relationship continued to produce real value. But the product roadmap — and, critically, the go-to-market strategy — pivoted to fit the market that actually existed.

Three signals that should put you in discovery mode, not execution mode

1. The marquee customer arrived through a relationship channel, not through a marketing channel. If your first big customer came through a personal introduction, an academic collaboration, or a mutual investor, that is not a sales process. That is a network. Networks do not scale.

2. The customer's internal champion is unusual. If your buyer is the rare individual at their organization who is willing to take risks on emerging technology, you have signal about that individual, not about that industry. Find out how many other people in their company think the way they do. Often, the answer is none.

3. The deal economics are non-standard. Co-development agreements, joint research grants, and equity-flavored partnerships look like sales but behave like partnerships. They tell you that this customer values you. They do not tell you what your product would be worth in an arms-length transaction with the next ten buyers.

What to do instead

The discipline is to treat your first marquee customer as a hypothesis generator, not a market thesis. Use the relationship to learn — about the buying process, the technical objections, the integration challenges, the organizational dynamics. Use the access to validate or invalidate the broader market assumption. The question you are trying to answer is not “how do we get more customers like this one?” The question is “does the rest of this market exist at all, and if it does, what does it actually look like?”

In DBC's case, the answer to that question turned out to be surprising — and far more valuable than another Merck would have been. The real market was not the one they had assumed. There was a translational research segment sitting between basic academic neuroscience research and pharma discovery, and that segment was ready to buy now. That is the subject of another post in this series.

The Merck-shaped success story you are about to chase may be the most expensive coincidence of your career. Test it before you bet on it.

The practical takeaway

If you have a marquee customer and you are tempted to scale against them, slow down for ninety days. Run thirty to fifty structured customer discovery conversations across the rest of the segment. If you find the pattern, scale with confidence — you have just discovered a market. If you do not find the pattern, you have just saved your company. Either outcome is worth the time.